Pharma Q2 Preview: Cipla to see steady qtr; higher profit growth for DRL https://ift.tt/6GwDM5T could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three brokerages, and net profit for the same period is expected to rise around 19% YoY.
NSE IFSC-SGX Connect may be fully operational by June https://ift.tt/XC89Iks this connectivity, global investors who are clients of SGX will be able to trade in Indian derivatives market remotely without having to set up a shop in India. Currently, only a few trades are being executed through the route.
Comments
Post a Comment